Journal article

Modulation of cellular radiation responses by histone deacetylase inhibitors

TC Karagiannis, A El-Osta

Oncogene | NATURE PUBLISHING GROUP | Published : 2006


Histone deacetylase (HDAC) inhibitors are emerging as a new class of targeted cancer chemotherapeutics. Several HDAC inhibitors are currently in clinical trials and promising anticancer effects at well-tolerated doses have been observed for both hematologic and solid cancers. HDAC inhibitors have been shown to induce cell-cycle and growth arrest, differentiation and in certain cases apoptosis in cell cultures and in vivo. However, it is known that these compounds induce varying responses in different cells and biological settings, and identifying their precise mechanisms of action is an area of great interest. Important findings are continually expanding our understanding of the cellular eff..

View full abstract

University of Melbourne Researchers